Clinical significance of circulating hepatocyte growth factor, a new risk marker of carotid atherosclerosis in patients with Type 2 diabetes

Satani, Kahori; Konya, Hiroyuki; Hamaguchi, Tomoya; Umehara, Akiko; Katsuno, Tomoyuki; Ishikawa, Tetsuya; Kohri, K.; Hasegawa, Yoshikazu; Suehiro, Akira; Kakishita, Eizo; Namba, Mitsuyoshi

doi:10.1111/j.1464-5491.2006.01849.x

Cited by 31 publications

(26 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Augmented intima-media thickness (IMT) has been demonstrated to be a substitute biomarker for prognosticating CV hazard [72] . In a study by Miyazaki et al [73] , stepwise regression analysis indicated plasma concentrations of ADMA to be remarkably related to carotid IMT.…”

Section: Adma and Carotid Intima-media Thicknessmentioning

confidence: 99%

Asymmetric dimethylarginine, a biomarker of cardiovascular complications in diabetes mellitus

Konya

Miuchi

Satani

et al. 2015

WJEM

View full text Add to dashboard Cite

Cardiovascular (CV) complications are an essential causal element of prospect in diabetes mellitus (DM), with carotid atherosclerosis being a common risk factor for prospective crisis of coronary artery diseases and/or cerebral infarction in DM subjects. From another point of view, asymmetric dimethylarginine (ADMA) has been established as an inhibitor of endogenous nitric oxide synthesis and the relationship between ADMA and arteriosclerosis has been reported. In our study with 87 type 2 DM (T2DM) patients, we have examined whether ADMA and other CV risk factors are the useful predictors of DMCV complications. After the measurement of the respective CV risk factors, we have followed the enrolled T2DM patients for 5 years. We have finally analyzed 77 patients. DMCV complications developed in 15 cases newly within 5 years, and 4 cases recurred. The concentrations of ADMA in plasma were markedly more elevated in 19 DM patients with CV complications than in 58 DM patients without CV complications. Urinary albumin (U-Alb), mean intimal-medial thickness (IMT) and ankle brachial index (ABI) were also higher in patients with CV complications. Multiple regression analyses showed that U-Alb had an influence on the high level of ADMA (standardized β = 6.59, P = 0.00014) independently of age, systolic BP, fibrinogen, mean IMT, plaque score, and ABI. The review indicates what is presently known regarding plasma ADMA that might be a new and meaningful biomarker of CV complications in DM subjects. Core tip: Asymmetric dimethylarginine (ADMA) is an emerging independent biomarker for prospective cardiovascular (CV) complications. In our study, the results show that the cases with a high level of ADMA could have diabetes mellitus CV (DMCV) complications in the future within five years. Furthermore, not only ADMA but also urinary albumin was associated with DMCV complications in the multiple regression analyses. The clinical acceptation of this parameter will rely on the availability of therapies to immediately reduce ADMA such as incretin-based drugs, which could support the part of ADMA as an etiologic risk factor.

show abstract

Section: Adma and Carotid Intima-media Thicknessmentioning

confidence: 99%

Asymmetric dimethylarginine, a biomarker of cardiovascular complications in diabetes mellitus

Konya

Miuchi

Satani

et al. 2015

WJEM

View full text Add to dashboard Cite

show abstract

“…HGF positively correlated betatrophin in insulin-treated patients. Satani et al (2006) found markedly higher serum HGF in T2DM patients than the normal range [75]. High HGF level is associated with prevalence of T2DM [76] and with depressed cardiovascular autonomic function and IR in T2DM patients [77].…”

Section: Discussionmentioning

confidence: 99%

Circulating Betatrophin and Hepatocyte Growth Factor in Type 2 Diabetic Patients: Their Relationship With Disease Prognosis

Alduraywish

2017

J Endocrinol Metab

View full text Add to dashboard Cite

Background: In Saudi Arabia, diabetes established itself as an epidemic that necessitates dissection of its predisposing factors and pathogenesis to set appropriate preventive measures. In a cross-sectional study, relationships between plasma betatrophin (BetaT) and hepatocyte growth factor (HGF) on one side, and, glycemic control, lipogram, anthropometric indices, treatment and prognosis on the other side were assessed in Saudi patients with type 2 diabetes mellitus (T2DM) vs. healthy controls.

show abstract

“…The other biomarkers that have been investigated: urinary 8-hydroxydeoxyguanosine (8-OHdG) (52), osteoprotegerin (53), hepatocyte growth factor (HGF) (54,55), matrix metalloproteinase-9 (MMP-9) (56), cystatin C (57), 1,5 anhydroglucitol (58, 59), neutrophil gelatinase-associated lipocaline (NGAL) (60), , HbA1c, fructosamine, glycated albumin (62).…”

Section: Urinary Proteins (Or Their Fragments) Found Associated With mentioning

confidence: 99%

Biomarkers for Diabetes Complications: The Results of Several Clinical Studies

Aslan¹

2011

Journal of Medical Biochemistry

View full text Add to dashboard Cite

Kratak sadr`aj: Dijabetes predstavlja ~est metaboli~ki poreme}aj, ~ije mikrovaskularne i makrovaskularne komplikacije doprinose smrti, invaliditetu i skra}enju o~e kivanog `ivotnog veka kod obolelih. Ova bolest podrazumeva velike tro{kove a pored pacijenta i njegove porodice poga|a i javno zdravlje, zajednice i dru{tvo. Dijabetes zahteva sve ve}i deo nacionalnih tro{kova zdravstva. Prevencija razvoja dijabetesa i njegovih komplikacija je va`an problem. U cilju razumevanja mehanizama razvoja i progresije komplikacija u dijabetesu vr{i se istra`ivanje biomarkera. U ovom radu dat je pregled biomarkera koji se preporu~uju u klini~koj praksi i pravilnicima za laboratorijsku medicinu i koji su istra`ivani radi predikcije ili dijagnostikovanja kom plikacija u dijabetesu. U sa`etom obliku su prikazani rezultati nekoliko klini~kih studija.Klju~ne re~i: dijabetes, biomarkeri, klini~ke studije Summary: Diabetes is a common metabolic disorder. Its microvascular and macrovascular complications contribute to death, disabilities, and reduction in life expectancy in diabetes. It is a costly disease, and affects not only the patient and family, but also the public health, communities and society. It takes an increasing proportion of the na tional health care expenditure. The prevention of the development of diabetes and its complications is a major concern. Biomarkers have been investigated for understanding the mechanisms of the development and progression of diabetic com plications. In this paper, the biomarkers which are re com mended in the clinical practice and laboratory medicine guidelines, and which have been investigated for prediction or diagnosis of diabetes complications, have been reviewed. The results of several clinical studies will be summarized.

show abstract

Clinical significance of circulating hepatocyte growth factor, a new risk marker of carotid atherosclerosis in patients with Type 2 diabetes

Abstract: Serum HGF concentration may be a new marker of atherosclerotic complications in patients with Type 2 DM.

Cited by 31 publications

References 24 publications

Asymmetric dimethylarginine, a biomarker of cardiovascular complications in diabetes mellitus

Asymmetric dimethylarginine, a biomarker of cardiovascular complications in diabetes mellitus

Circulating Betatrophin and Hepatocyte Growth Factor in Type 2 Diabetic Patients: Their Relationship With Disease Prognosis

Biomarkers for Diabetes Complications: The Results of Several Clinical Studies

Contact Info

Product

Resources

About